Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | ap endonuclease, putative | 0.0022 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0022 | 0 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0022 | 0 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0022 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0042 | 1 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0022 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0022 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0042 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0042 | 1 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0042 | 1 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0042 | 1 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0042 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0022 | 0 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0022 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0022 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0022 | 0 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0022 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0022 | 0 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0022 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0042 | 1 | 1 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0022 | 0 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0022 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0042 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.